Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer

Preliminary Results

Fable Zustovich, Alessandra Ferro, Giuseppe Lombardi, Patrizia Farina, Vittorina Zagonel

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Bevacizumab is a recombinant humanized monoclonal antibody that obstructs the vascular endothelial growth factor (VEGF) pathway. Despite its extensive employment in the treatment of primary tumors of the brain, experience of brain metastatic disease, a frequent complication in patients with lung cancer, is very limited. On the basis of the strong antiedemigenous effect and no risk of intracranial bleeding, we administered a bevacizumab-based chemotherapy to patients with non-small-cell lung cancer (NSCLC) and symptomatic metastatic brain lesions who were not suitable candidates for a specific local therapy.

METHODS: The patients received bevacizumab 7.5 mg/kg and cisplatin 75 mg/m(2) on day 1, and gemcitabine 1,250 mg/m(2) on days 1 and 8, every 21 days.

RESULTS: We studied 13 patients with clinical and radiological progressive brain metastases; the majority had a treatment-naïve disease. Bevacizumab-based chemotherapy was found to be well tolerated and effective: progression-free survival (PFS) was 9.1 months (range: 0.9-39.2+) and overall survival (OS) was 9.6 months (range 3-41.5+).

CONCLUSIONS: Bevacizumab-based therapy proved to be feasible and safe. The PFS and the OS data are very encouraging as well as the symptomatic benefit due to bevacizumab's high capacity to provide a long-lasting decrease of perilesional edema.

Original languageEnglish
Pages (from-to)294-299
Number of pages6
JournalChemotherapy
Volume60
Issue number5-6
DOIs
Publication statusPublished - 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
gemcitabine
Disease-Free Survival
Therapeutics
Antibodies, Monoclonal, Humanized
Drug Therapy
Survival
Brain Diseases
Brain Neoplasms
Vascular Endothelial Growth Factor A
Cisplatin
Bevacizumab
Lung Neoplasms
Edema
Hemorrhage

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer : Preliminary Results. / Zustovich, Fable; Ferro, Alessandra; Lombardi, Giuseppe; Farina, Patrizia; Zagonel, Vittorina.

In: Chemotherapy, Vol. 60, No. 5-6, 2014, p. 294-299.

Research output: Contribution to journalArticle

@article{8bed840ad1544e9d929f0b8074861eab,
title = "Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results",
abstract = "BACKGROUND: Bevacizumab is a recombinant humanized monoclonal antibody that obstructs the vascular endothelial growth factor (VEGF) pathway. Despite its extensive employment in the treatment of primary tumors of the brain, experience of brain metastatic disease, a frequent complication in patients with lung cancer, is very limited. On the basis of the strong antiedemigenous effect and no risk of intracranial bleeding, we administered a bevacizumab-based chemotherapy to patients with non-small-cell lung cancer (NSCLC) and symptomatic metastatic brain lesions who were not suitable candidates for a specific local therapy.METHODS: The patients received bevacizumab 7.5 mg/kg and cisplatin 75 mg/m(2) on day 1, and gemcitabine 1,250 mg/m(2) on days 1 and 8, every 21 days.RESULTS: We studied 13 patients with clinical and radiological progressive brain metastases; the majority had a treatment-na{\"i}ve disease. Bevacizumab-based chemotherapy was found to be well tolerated and effective: progression-free survival (PFS) was 9.1 months (range: 0.9-39.2+) and overall survival (OS) was 9.6 months (range 3-41.5+).CONCLUSIONS: Bevacizumab-based therapy proved to be feasible and safe. The PFS and the OS data are very encouraging as well as the symptomatic benefit due to bevacizumab's high capacity to provide a long-lasting decrease of perilesional edema.",
author = "Fable Zustovich and Alessandra Ferro and Giuseppe Lombardi and Patrizia Farina and Vittorina Zagonel",
year = "2014",
doi = "10.1159/000376605",
language = "English",
volume = "60",
pages = "294--299",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "5-6",

}

TY - JOUR

T1 - Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer

T2 - Preliminary Results

AU - Zustovich, Fable

AU - Ferro, Alessandra

AU - Lombardi, Giuseppe

AU - Farina, Patrizia

AU - Zagonel, Vittorina

PY - 2014

Y1 - 2014

N2 - BACKGROUND: Bevacizumab is a recombinant humanized monoclonal antibody that obstructs the vascular endothelial growth factor (VEGF) pathway. Despite its extensive employment in the treatment of primary tumors of the brain, experience of brain metastatic disease, a frequent complication in patients with lung cancer, is very limited. On the basis of the strong antiedemigenous effect and no risk of intracranial bleeding, we administered a bevacizumab-based chemotherapy to patients with non-small-cell lung cancer (NSCLC) and symptomatic metastatic brain lesions who were not suitable candidates for a specific local therapy.METHODS: The patients received bevacizumab 7.5 mg/kg and cisplatin 75 mg/m(2) on day 1, and gemcitabine 1,250 mg/m(2) on days 1 and 8, every 21 days.RESULTS: We studied 13 patients with clinical and radiological progressive brain metastases; the majority had a treatment-naïve disease. Bevacizumab-based chemotherapy was found to be well tolerated and effective: progression-free survival (PFS) was 9.1 months (range: 0.9-39.2+) and overall survival (OS) was 9.6 months (range 3-41.5+).CONCLUSIONS: Bevacizumab-based therapy proved to be feasible and safe. The PFS and the OS data are very encouraging as well as the symptomatic benefit due to bevacizumab's high capacity to provide a long-lasting decrease of perilesional edema.

AB - BACKGROUND: Bevacizumab is a recombinant humanized monoclonal antibody that obstructs the vascular endothelial growth factor (VEGF) pathway. Despite its extensive employment in the treatment of primary tumors of the brain, experience of brain metastatic disease, a frequent complication in patients with lung cancer, is very limited. On the basis of the strong antiedemigenous effect and no risk of intracranial bleeding, we administered a bevacizumab-based chemotherapy to patients with non-small-cell lung cancer (NSCLC) and symptomatic metastatic brain lesions who were not suitable candidates for a specific local therapy.METHODS: The patients received bevacizumab 7.5 mg/kg and cisplatin 75 mg/m(2) on day 1, and gemcitabine 1,250 mg/m(2) on days 1 and 8, every 21 days.RESULTS: We studied 13 patients with clinical and radiological progressive brain metastases; the majority had a treatment-naïve disease. Bevacizumab-based chemotherapy was found to be well tolerated and effective: progression-free survival (PFS) was 9.1 months (range: 0.9-39.2+) and overall survival (OS) was 9.6 months (range 3-41.5+).CONCLUSIONS: Bevacizumab-based therapy proved to be feasible and safe. The PFS and the OS data are very encouraging as well as the symptomatic benefit due to bevacizumab's high capacity to provide a long-lasting decrease of perilesional edema.

UR - http://www.scopus.com/inward/record.url?scp=84989803740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989803740&partnerID=8YFLogxK

U2 - 10.1159/000376605

DO - 10.1159/000376605

M3 - Article

VL - 60

SP - 294

EP - 299

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 5-6

ER -